KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Intangibles (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Intangibles for 15 consecutive years, with $569.5 million as the latest value for Q4 2025.

  • Quarterly Intangibles rose 9.11% to $569.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $569.5 million through Dec 2025, up 9.11% year-over-year, with the annual reading at $569.5 million for FY2025, 9.11% up from the prior year.
  • Intangibles for Q4 2025 was $569.5 million at Supernus Pharmaceuticals, down from $623.5 million in the prior quarter.
  • The five-year high for Intangibles was $784.7 million in Q4 2021, with the low at $346.6 million in Q3 2021.
  • Average Intangibles over 5 years is $587.0 million, with a median of $589.8 million recorded in 2023.
  • The sharpest move saw Intangibles skyrocketed 1421.42% in 2021, then decreased 15.75% in 2024.
  • Over 5 years, Intangibles stood at $784.7 million in 2021, then dropped by 10.48% to $702.5 million in 2022, then dropped by 14.6% to $599.9 million in 2023, then dropped by 13.0% to $521.9 million in 2024, then rose by 9.11% to $569.5 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $569.5 million, $623.5 million, and $481.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.